Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.1823
- Book/Share 15.7357
- PB 7.1631
- Debt/Equity 1.2679
- CurrentRatio 1.3154
- ROIC 0.149
- MktCap 140459342891.0
- FreeCF/Share 7.5253
- PFCF 14.9919
- PE 22.3315
- Debt/Assets 0.4477
- DivYield 0.0277
- ROE 0.3294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
News
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
Read More
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Read More
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Read More
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
Read More
Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp.
Published: April 02, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
GILD or AMGN: Which Is the Better Value Stock Right Now?
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Read More
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Published: March 23, 2025 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
Read More
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Published: March 19, 2025 by: Barrons
Sentiment: Negative
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
Read More
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
Published: March 14, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch I think we'll get started. Hi, everyone.
Read More
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Published: March 11, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in T.
Read More
S&P 500 ETF's Worst Week Since September: 5 Top Stocks Poised to Rise
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
These top-ranked stocks of the S&P 500 index have gained in the index's worst week since September. These stocks have more room to run.
Read More
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Read More
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.
Read More
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Read More
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
During this time of heightened market volatility, it pays to be invested in the right places.
Read More
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Published: March 03, 2025 by: Reuters
Sentiment: Negative
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Read More
Why Gilead Sciences Remains A Buy After A 40% Rally
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.
Read More
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600